Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients With Inflammatory Bowel Disease Results From a Tertiary Referral Center
Tarih
2021Yazar
Tuncer, Murat
Erzin, Yusuf
Demir, Nurhan
Celik, Sinem
HATEMİ, ALİ İBRAHİM
ÇELİK, Aykut Ferhat
EŞKAZAN, Tuğçe
Bozcan, Selma
Atay, Kadri
Yildirim, Suleyman
Üst veri
Tüm öğe kaydını gösterÖzet
Objective The aim of the study was to identify the frequency of azathioprine-induced acute pancreatitis (AZA-AP) and related factors. Methods Seven hundred eighty-seven inflammatory bowel disease (IBD) patients on AZA therapy were retrospectively analyzed. Azathioprine-induced AP was diagnosed with positive imaging and/or an at least 3-fold increased amylase level, in presence of typical abdominal pain. The AZA-AP group was compared with patients on AZA therapy with no history of pancreatitis and 4 numerical adjacent cases with the same diagnosis were selected (group B). Results Fifty-four patients developed gastrointestinal symptoms (6.9%); however, only half of them (26 of 54) had pancreatitis, except 1, all within the first 2 months under AZA. When the AZA-AP group was compared with group B, only budesonide usage and active smoking were significantly more common in group A (46.2% vs 25%, P = 0.034, and 77% vs 51%, P = 0.017, respectively). Active smoking was the only independent risk factor for AZA-AP development (odds ratio, 3.208 [95% confidence interval, 1.192-8.632]). Conclusions All IBD patients developed AZA-AP nearly all within the first 2 months. Azathioprine intolerance may be a hidden diagnosis in at least half of the patients with AZA-AP symptoms. All smoker IBD patients should be monitored closely for AZA-AP development.
Koleksiyonlar
- Makale [92797]